Predictors of Primary Response to Biologic Treatment Anti-TNF, Vedolizumab, and Ustekinumab in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

摘要

Background: Inflammatory bowel diseases [IBD]-ulcerative colitis and Crohn's disease-are commonly treated with biologic drugs. However, only approximately two-thirds of patients have an initial response to these therapies. Personalised medicine has the potential to optimise efficacy, decrease the risk of adverse drug events, and reduce costs by establishing the most suitable therapy for a selected patient.